In Brief: Hi-Tech Pharmacal, OTC firm warned on water tests, John Taylor to leave FDA, NAD and ASA review claims
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal profits plummet; FDA warns OTC firm about GMPs; John Taylor to leave FDA; NAD refers claims for Vysera-CLS to FTC; Circulation Patch It claims lack support – ASA; and U.K. liquid OTC recalls.